Piper Sandler analyst David Amsellem lowered the firm’s price target on Collegium Pharmaceutical (COLL) to $36 from $37 and keeps a Neutral ...

Piper Sandler analyst David Amsellem maintained a Hold rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price target ...

China Universal Asset Management Co. Ltd. boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...